ABC logo

AmerisourceBergen Corporation (ABC) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

AmerisourceBergen Corporation (ABC), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 45/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 16 Mar 2026
45/100 AI Puanı

AmerisourceBergen Corporation (ABC) Sağlık ve Boru Hattı Genel Bakışı

CEOSteven H. Collis
Çalışanlar46000
MerkezConshohocken, US
Halka Arz Yılı1995
SektörHealthcare

AmerisourceBergen Corporation is a global pharmaceutical distributor providing brand-name and generic drugs, healthcare products, and related services. With a focus on pharmaceutical distribution and integrated manufacturer services, the company serves a diverse customer base, including hospitals, pharmacies, and veterinary practices, navigating a complex regulatory landscape.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 16 Mar 2026

Yatırım Tezi

AmerisourceBergen presents a stable investment opportunity within the healthcare sector, driven by its essential role in pharmaceutical distribution. The company's consistent revenue stream is supported by long-term contracts and a diversified customer base. A key value driver is the increasing demand for specialty pharmaceuticals and related services, where AmerisourceBergen has established a strong presence. However, investors may want to evaluate the relatively low profit margin of 0.5% and the potential impact of regulatory changes on drug pricing and distribution. The company's beta of 0.56 suggests lower volatility compared to the overall market. The dividend yield of 0.66% provides a modest income stream.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $36.15 billion, reflecting its significant presence in the pharmaceutical distribution market.
  • P/E ratio of 41.82, indicating investor expectations for future earnings growth.
  • Gross margin of 3.3%, highlighting the competitive pricing environment in the pharmaceutical distribution industry.
  • Dividend yield of 0.66%, providing a modest return for investors.
  • Beta of 0.56, suggesting lower volatility compared to the broader market.

Rakipler & Benzerleri

Güçlü Yönler

  • Extensive distribution network
  • Strong relationships with pharmaceutical manufacturers
  • Comprehensive service offerings
  • Scale and purchasing power

Zayıflıklar

  • Low profit margin
  • Dependence on pharmaceutical manufacturers
  • Exposure to regulatory changes
  • High debt levels

Katalizörler

  • Ongoing: Increasing demand for specialty pharmaceuticals, driving growth in related services.
  • Ongoing: Strategic partnerships with pharmaceutical manufacturers to enhance product access and distribution.
  • Upcoming: Potential acquisitions of complementary businesses to expand service offerings and geographic reach.
  • Ongoing: Investments in technology and infrastructure to improve supply chain efficiency.

Riskler

  • Potential: Increased competition from other pharmaceutical distributors and manufacturers.
  • Ongoing: Drug pricing pressures and regulatory changes impacting reimbursement rates.
  • Potential: Economic downturn affecting demand for healthcare products and services.
  • Ongoing: Dependence on key pharmaceutical manufacturers for product supply.

Büyüme Fırsatları

  • Expansion of Specialty Pharmaceutical Services: The increasing demand for specialty pharmaceuticals, particularly in oncology and immunology, presents a significant growth opportunity for AmerisourceBergen. By expanding its services for specialty drug manufacturers and providers, including data analytics and patient support programs, the company can capture a larger share of this high-growth market. The specialty pharmaceutical market is projected to reach $400 billion by 2026, offering substantial revenue potential.
  • Strategic Acquisitions and Partnerships: AmerisourceBergen can pursue strategic acquisitions and partnerships to expand its service offerings and geographic reach. Acquiring companies with complementary capabilities, such as specialty pharmacies or healthcare technology providers, can enhance its competitive position and drive revenue growth. Partnerships with pharmaceutical manufacturers can also strengthen its supply chain and improve access to innovative therapies. These initiatives can be implemented within the next 1-3 years.
  • Growth in Animal Health Market: The animal health market is experiencing steady growth, driven by increasing pet ownership and rising demand for animal healthcare products. AmerisourceBergen's Other segment, which includes animal health products and services, can capitalize on this trend by expanding its product portfolio and distribution network. The global animal health market is expected to reach $75 billion by 2028, providing a significant growth opportunity.
  • Enhancement of Supply Chain Efficiency: Improving supply chain efficiency can reduce costs and enhance customer satisfaction. AmerisourceBergen can invest in technology and infrastructure to optimize its distribution network, improve inventory management, and streamline order processing. By leveraging data analytics and automation, the company can identify and address inefficiencies in the supply chain, leading to improved profitability and competitiveness. This is an ongoing opportunity.
  • Expansion of Integrated Manufacturer Services: The demand for integrated manufacturer services, such as clinical trial support and product commercialization, is growing as pharmaceutical companies seek to outsource non-core activities. AmerisourceBergen can expand its service offerings in this area to capture a larger share of the market. By providing comprehensive solutions that support the entire product lifecycle, the company can become a strategic partner for pharmaceutical manufacturers and drive long-term revenue growth. This expansion can occur over the next 2-5 years.

Fırsatlar

  • Expansion of specialty pharmaceutical services
  • Strategic acquisitions and partnerships
  • Growth in animal health market
  • Enhancement of supply chain efficiency

Tehditler

  • Increased competition
  • Drug pricing pressures
  • Regulatory changes
  • Economic downturn

Rekabet Avantajları

  • Extensive distribution network: AmerisourceBergen has a well-established distribution network that reaches a wide range of healthcare providers.
  • Strong relationships with pharmaceutical manufacturers: The company has long-standing relationships with major pharmaceutical manufacturers, ensuring access to a wide range of products.
  • Comprehensive service offerings: AmerisourceBergen offers a comprehensive suite of services, including pharmaceutical distribution, pharmacy management, and integrated manufacturer services.
  • Scale and purchasing power: The company's scale and purchasing power allow it to negotiate favorable pricing with manufacturers and achieve economies of scale.

ABC Hakkında

AmerisourceBergen Corporation, established in 2001 and headquartered in Conshohocken, Pennsylvania, is a leading global healthcare solutions provider focused on pharmaceutical distribution and related services. The company operates through two primary segments: Pharmaceutical Distribution and Other. The Pharmaceutical Distribution segment distributes a wide range of pharmaceutical products, including brand-name and generic drugs, over-the-counter healthcare products, and home healthcare supplies. This segment serves various healthcare providers, such as acute care hospitals, retail pharmacies, mail-order pharmacies, medical clinics, and long-term care facilities. AmerisourceBergen also offers pharmacy management, staffing, and consulting services, along with supply management software and packaging solutions. The Other segment provides integrated manufacturer services, including clinical trial support, product post-approval services, and commercialization support. Additionally, this segment offers specialty transportation and logistics services for the biopharmaceutical industry and distributes pharmaceuticals, vaccines, and other products to the companion and production animal markets. AmerisourceBergen's extensive distribution network and comprehensive service offerings position it as a key player in the pharmaceutical supply chain, connecting manufacturers and healthcare providers to improve patient access to medications and healthcare solutions.

Ne Yaparlar

  • Distributes brand-name and generic pharmaceuticals to healthcare providers.
  • Provides over-the-counter healthcare products and home healthcare supplies.
  • Offers pharmacy management, staffing, and consulting services.
  • Develops and implements supply management software for healthcare providers.
  • Provides packaging solutions to institutional and retail healthcare providers.
  • Distributes plasma and other blood products, injectable pharmaceuticals, and vaccines.
  • Offers data analytics and outcomes research for biotechnology and pharmaceutical manufacturers.
  • Provides integrated manufacturer services, including clinical trial support and product commercialization.

İş Modeli

  • Generates revenue through the distribution of pharmaceutical products to healthcare providers.
  • Provides value-added services, such as pharmacy management and consulting, to generate additional revenue.
  • Offers integrated manufacturer services to pharmaceutical companies, creating a diversified revenue stream.

Sektör Bağlamı

AmerisourceBergen operates within the medical distribution industry, a sector characterized by consolidation and increasing regulatory scrutiny. The industry is driven by the growing demand for pharmaceuticals, driven by an aging population and advancements in medical treatments. Key trends include the rise of specialty pharmaceuticals, the increasing importance of supply chain efficiency, and the growing focus on patient outcomes. AmerisourceBergen competes with other major distributors and faces pressure from manufacturers seeking to control distribution channels. The industry is subject to regulations related to drug pricing, safety, and distribution practices.

Kilit Müşteriler

  • Acute care hospitals and health systems
  • Independent and chain retail pharmacies
  • Mail order pharmacies
  • Medical clinics
  • Long-term care and alternate site pharmacies
AI Güveni: 83% Güncellendi: 16 Mar 2026

Finansallar

Grafik & Bilgi

AmerisourceBergen Corporation (ABC) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

ABC için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

ABC için Wall Street fiyat hedefi analizi.

MoonshotScore

45/100

Bu puan ne anlama geliyor?

MoonshotScore, ABC'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Steven H. Collis

Chairman, President and Chief Executive Officer

Steven H. Collis has served as Chairman, President & CEO of AmerisourceBergen since 2011. Prior to this, he held various leadership positions within the company, including President and Chief Operating Officer. His extensive experience in the pharmaceutical industry spans over two decades, providing him with a deep understanding of the market dynamics and challenges. He is known for his strategic vision and focus on innovation.

Sicil: Under Steven H. Collis's leadership, AmerisourceBergen has experienced significant growth and expansion, solidifying its position as a leading global healthcare solutions provider. He has overseen key acquisitions and strategic initiatives that have enhanced the company's service offerings and geographic reach. Collis has also been instrumental in driving innovation and improving operational efficiency, contributing to the company's financial performance.

ABC Healthcare Hisse Senedi SSS

ABC için değerlendirilmesi gereken temel faktörler nelerdir?

AmerisourceBergen Corporation (ABC) şu anda yapay zeka skoru 45/100, düşük puanı gösteriyor. Temel güçlü yan: Extensive distribution network. İzlenmesi gereken birincil risk: Potential: Increased competition from other pharmaceutical distributors and manufacturers.. Bu bir finansal tavsiye değildir.

ABC MoonshotScore'u nedir?

ABC şu anda MoonshotScore'da 45/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

ABC verileri ne sıklıkla güncellenir?

ABC fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler ABC hakkında ne diyor?

ABC için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

ABC'a yatırım yapmanın riskleri nelerdir?

ABC için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Increased competition from other pharmaceutical distributors and manufacturers.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

ABC'ın P/E oranı nedir?

ABC için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için ABC'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

ABC aşırı değerli mi, yoksa düşük değerli mi?

AmerisourceBergen Corporation (ABC)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

ABC'ın temettü verimi nedir?

AmerisourceBergen Corporation (ABC) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Information is based on available data and may be subject to change.
  • AI analysis is pending and may provide further insights.
Veri Kaynakları

Popüler Hisseler